Repeating the Third Year?
Duke University would have avoided embarrassment, a misconduct investigation and a lawsuit, had its top administrators paid closer attention to a thoughtful report by a medical student who saw problems in the lab of the disgraced scientist Anil Potti.
Polaris Group's lead product candidate, ADI-PEG 20 (pegylated arginine deiminase), received orphan drug designations for the treatment of malignant pleural mesothelioma in the U.S. and the European Union.
Amgen and Kite Pharma entered into a strategic research collaboration and license agreement to develop and commercialize novel Chimeric Antigen Receptor T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's array of cancer targets.
Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co. Ltd., completed its rolling New Drug Application submission to FDA for TAS-102 (trifluridine and tipiracil hydrochloride). TAS-102 is an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer.
NCI DIRECTOR HAROLD VARMUS, in a new year's message to NCI staff and grantees, outlined the NCI's goals and obstacles for 2015 as the institute pursues new trials in precision medicine.
DARIO ALTIERI was named CEO of The Wistar Institute, following the announced retirement of President and CEO Russel Kaufman, effective March 2. Altieri will continue to serve as director of the Wistar Cancer Center, and Kaufman will become president emeritus.
FDA approved a supplemental biologics license application for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia.
FDA granted Fast Track designation to SGX301 (synthetic hypericin) for the first-line treatment of cutaneous T-cell lymphoma.
Are Cancer Drugs Getting Better? FDA’s Richard Pazdur Says, “Yes” A meeting of the FDA Oncologic Drugs Advisory Committee has become a rare occurrence. Why? Because cancer drugs are getting better, as are applications for their approval, said Richard Pazdur, director of the FDA Office of Hematology and Oncology Products. “Drug development is much more […]
